evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) leads to lower CMV infection compared with calcineurin inhibitors (CNI): main outcomes (high certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: primary outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to lower CMV infection compared with antimetabolites: primary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).

1 finding from 1 review